Jason Jones, MD
Family Medicine · Garner, NCNPI 1275595407
Payments from drug & device makers
Across 264 payments — averaging $19.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$767
- Preventric Diagnostics, Inc.$647
- Boehringer Ingelheim$594
- Lilly USA, LLC$334
- AbbVie$299
- Amgen$208
- plus $2K from 33 others
What the payments were for
- Food & beverage$5,016100%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 46 | $767 |
| Preventric Diagnostics, Inc. | 2 | $647 |
| Boehringer Ingelheim | 40 | $594 |
| Lilly USA, LLC | 19 | $334 |
| AbbVie | 17 | $299 |
| Amgen | 14 | $208 |
| Abbott | 10 | $193 |
| AstraZeneca | 12 | $179 |
| Pfizer | 12 | $172 |
| Bausch Health US, LLC | 7 | $150 |
| Exact Sciences | 6 | $116 |
| Cook Medical LLC | 1 | $112 |
| Merck | 9 | $112 |
| Boston Scientific | 2 | $101 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $95 |
| Johnson & Johnson | 8 | $93 |
| Otsuka America Pharmaceutical, Inc. | 5 | $91 |
| Astellas Pharma US Inc | 5 | $85 |
| GSK | 5 | $81 |
| Sumitomo Pharma America, Inc. | 4 | $74 |
| Gilead | 3 | $65 |
| Medtronic | 3 | $60 |
| Idorsia Pharmaceuticals US Inc | 3 | $55 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $41 |
| Sanofi-aventis U.S. LLC | 3 | $39 |
| Kowa Pharmaceuticals America, Inc. | 3 | $38 |
| Axsome Therapeutics, Inc. | 2 | $32 |
| Amarin Pharma, Inc. | 2 | $27 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| Esperion Therapeutics, Inc. | 1 | $18 |
| Corium, LLC | 1 | $17 |
| Ardelyx, Inc. | 1 | $17 |
| Sandoz | 1 | $15 |
| Biohaven Pharmaceuticals, Inc. | 1 | $14 |
| Exeltis, USA Inc. | 1 | $13 |
| Cranial Technologies, Inc | 1 | $13 |
| Shire North American Group Inc | 1 | $12 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $12 |
| Therapeuticsmd, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,023 in reported general payments places this provider in the 85th percentile of 3,444 family medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 130 | $168,925 |
| OzempicSemaglutide | 106 | $100,943 |
| RybelsusSemaglutide | 61 | $65,247 |
| EliquisApixaban | 73 | $55,791 |
| MounjaroTirzepatide | 54 | $54,425 |
| JanuviaSitagliptin Phosphate | 40 | $33,116 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 27 | $21,477 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $17,315 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 109 | $9,680 |
| Novolog FlexpenInsulin Aspart | 40 | $6,870 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $6,664 |
| SymbicortBudesonide/Formoterol Fumarate | 15 | $6,027 |
| BelsomraSuvorexant | 13 | $5,544 |
| Wixela InhubFluticasone Propion/Salmeterol | 35 | $5,481 |
| PremarinEstrogens, Conjugated | 18 | $4,973 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $594 | $168,925130 claims |
| Novo NordiskOzempic, Rybelsus | $767 | $166,189167 claims |
| PfizerEliquis, Premarin | $172 | $60,76491 claims |
| Lilly USA, LLCMounjaro, Humalog | $334 | $56,90770 claims |
| MerckJanuvia, Belsomra | $112 | $38,66053 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $81 | $28,14144 claims |
| AstraZenecaSymbicort | $179 | $6,02715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,444 family medicine providers in North Carolina.
Other family medicine in Garner
- Domingo Rodriguez-CueGarner$253K
- Barton WilliamsWilmington$17.3M
- Alexander MurrayGreensboro$13M
- Arin PiramzadianJacksonville$13M
- Jonathan WilsonHickory$12.7M
- George RaadCharlotte$7.7M
- Cecil FarringtonSalisbury$6.4M
- Christian MartinShelby$5.4M
- John EarlHickory$4.7M
- Patrick MorganteHavelock$4.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.